1. Dysregulation of miRNA expression and excitation in MEF2C autism patient hiPSC-neurons and cerebral organoids
- Author
-
Trudler, Dorit, Ghatak, Swagata, Bula, Michael, Parker, James, Talantova, Maria, Luevanos, Melissa, Labra, Sergio, Grabauskas, Titas, Noveral, Sarah Moore, Teranaka, Mayu, Schahrer, Emily, Dolatabadi, Nima, Bakker, Clare, Lopez, Kevin, Sultan, Abdullah, Patel, Parth, Chan, Agnes, Choi, Yongwook, Kawaguchi, Riki, Stankiewicz, Pawel, Garcia-Bassets, Ivan, Kozbial, Piotr, Rosenfeld, Michael G., Nakanishi, Nobuki, Geschwind, Daniel H., Chan, Shing Fai, Lin, Wei, Schork, Nicholas J., Ambasudhan, Rajesh, and Lipton, Stuart A.
- Abstract
MEF2C is a critical transcription factor in neurodevelopment, whose loss-of-function mutation in humans results in MEF2C haploinsufficiency syndrome (MHS), a severe form of autism spectrum disorder (ASD)/intellectual disability (ID). Despite prior animal studies of MEF2Cheterozygosity to mimic MHS, MHS-specific mutations have not been investigated previously, particularly in a human context as hiPSCs afford. Here, for the first time, we use patient hiPSC-derived cerebrocortical neurons and cerebral organoids to characterize MHS deficits. Unexpectedly, we found that decreased neurogenesis was accompanied by activation of a micro-(mi)RNA-mediated gliogenesis pathway. We also demonstrate network-level hyperexcitability in MHS neurons, as evidenced by excessive synaptic and extrasynaptic activity contributing to excitatory/inhibitory (E/I) imbalance. Notably, the predominantly extrasynaptic (e)NMDA receptor antagonist, NitroSynapsin, corrects this aberrant electrical activity associated with abnormal phenotypes. During neurodevelopment, MEF2C regulates many ASD-associated gene networks, suggesting that treatment of MHS deficits may possibly help other forms of ASD as well.
- Published
- 2024
- Full Text
- View/download PDF